

# SCIENTIFIC PROGRAM

## WEDNESDAY, SEPTEMBER 17, 2008

08.30-10.00	Teaching Course 1	Room 520A
	<b>Overview of MS for the Non-Clinician</b> Jointly sponsored with EndMS/MS Society of Canada Course organizer: Ruth Ann Marrie (Winnipeg, Manitoba, Canada)	
08.30	<b>Introduction</b> Ruth Ann Marrie	
08.50	<b>MRI: terminology, diagnosis, uses in clinical trials</b> Anthony Traboulsee (Vancouver, British Columbia, Canada)	
09.30	<b>Disability scales in MS (EDSS/ MSFC)</b> François Bethoux (Cleveland, Ohio, USA)	
08.30-10.00	Teaching Course 2	Room 520B
	<b>MS Mimics: Identification and Treatment</b> Course organizer: Brian Weinshenker (Rochester, Minnesota, USA)	
08.30	<b>Introduction</b> Brian Weinshenker	
08.40	<b>Approach to identifying MS mimics</b> Michael Hutchinson (Dublin, Ireland)	
09.05	<b>Neuromyelitis optica and NMO spectrum disorders</b> Brian Weinshenker	
09.25	<b>Acute disseminated encephalomyelitis</b> Brenda Banwell (Toronto, Ontario, Canada)	
09.45	<b>Discussion/Questions</b>	
08.30-10.00	Teaching Course 3	Room 520C
	<b>Immunology of MS</b> Jointly sponsored with FOCiS (Federation of Clinical Immunology Societies) Course organizer: Andrew Lichtman (Boston, Massachusetts, USA)	
08.30	<b>Update on immunology</b> Andrew Lichtman	
09.10	<b>Update on autoimmunity</b> Amit Bar-Or (Montréal, Québec, Canada)	
09.50	<b>Questions and answers</b>	
08.30-10.00	Teaching Course 4	Room 524B
	<b>MS Genetics and Epidemiology</b> Course organizer: Jorge Oksenberg (San Francisco, California, USA)	
08.30	<b>Introduction</b> Jorge Oksenberg	
08.35	<b>The environment and MS</b> Alberto Ascherio (Boston, Massachusetts, USA)	
09.00	<b>Genome-wide association studies in MS</b> Stephen Sawcer (Cambridge, United Kingdom)	
09.25	<b>Beyond SNPs and transcripts: pathways and networks analysis in MS</b> Sergio Baranzini (San Francisco, California, USA)	
09.50	<b>Questions and answers</b>	

# SCIENTIFIC PROGRAM

## WEDNESDAY, SEPTEMBER 17, 2008 (CONT.)

08.30-10.00	Teaching Course 5	Room 524C
	<p>Diagnosis of MS and Monitoring Treatment: Application of Conventional MRI            Jointly sponsored with MAGNIMS (Magnetic Imaging in MS)            Course organizer: Xavier Montalban (Barcelona, Spain)</p>	
08.35	<p>MRI protocol and indications            David Li (Vancouver, British Columbia, Canada)</p>	
08.50	<p>Clinically isolated syndromes: update on MRI criteria            Alex Rovira (Barcelona, Spain)</p>	
09.05	<p>Spinal cord MRI : Clinical applications and technical issues            David Miller (London, United Kingdom)</p>	
09.20	<p>Atypical MRI presentations            Franz Fazekas (Graz, Austria)</p>	
09.35	<p>Predicting treatment response to interferon using MRI            Jack Simon (Denver, Colorado, USA)</p>	
09.50	<p>Questions and answers</p>	
10.00-10.30	Coffee Break	Foyer outside Rooms 520 and 524
10.30-12.00	Teaching Course 6	Room 520A
	<p>Overview of MS for the Non-Clinician (continued)            Jointly sponsored with EndMS/MS Society of Canada            Course organizer: Ruth Ann Marrie (Winnipeg, Manitoba, Canada)</p>	
10.30	<p>Immunology: terminology, relation to current medications, and medications under study            Nathalie Arbour (Montréal, Québec, Canada)</p>	
11.15	<p>Cognition in MS: focus on issues in trials            John Fisk (Halifax, Nova Scotia, Canada)</p>	
11.45	<p>Perspective on who gets MS and their issues            Video presentation</p>	
11.55	<p>Questions and answers/Closing remarks            Ruth Ann Marrie</p>	
10.30-12.00	Teaching Course 7	Room 520B
	<p>MS Treatments: Conventional, Emerging, Rescue            Course organizer: Hillel Panitch (Burlington, Vermont, USA)</p>	
10.30	<p>Conventional therapies            Hillel Panitch</p>	
10.55	<p>Emerging therapies            Timothy Vollmer (Denver, Colorado, USA)</p>	
11.30	<p>Rescue therapies            Brian Weinshenker (Rochester, Minnesota, USA)</p>	
11.55	<p>Questions and answers</p>	

# SCIENTIFIC PROGRAM

## WEDNESDAY, SEPTEMBER 17, 2008 (CONT.)

10.30-12.00	Teaching Course 8	Room 520C
	<b>Pathology of MS: Fundamentals and New Ideas</b> Course organizer: Samuel Ludwin (Kingston, Ontario, Canada)	
10.30	<b>New information on inflammatory changes in MS</b> Hans Lassman (Vienna, Austria)	
10.55	<b>Axonal and cortical changes in MS</b> Wolfgang Brück (Göttingen, Germany)	
11.30	<b>Remyelination in MS: mechanisms, assessment, and therapeutic potential</b> Samuel Ludwin	
11.55	Questions and answers	
10.30-12.00	Teaching Course 9	Room 524B
	<b>MS and Vision: The Disease in Microcosm</b> Course organizer: Peter Calabresi (Baltimore, Maryland, USA)	
10.30	<b>Pupils and ocular motility</b> Elliot Frohman (Dallas, Texas, USA)	
10.55	<b>Visual acuity and OCT</b> Laura Balcer (Philadelphia, Pennsylvania, USA)	
11.30	<b>OCT and axon degeneration</b> Peter Calabresi	
11.55	Questions and answers	
10.30-12.00	Teaching Course 10	Room 524C
	<b>Understanding Disability: Advanced MRI Techniques</b> Jointly sponsored with MAGNIMS (Magnetic Imaging in MS) Course organizer: Frederik Barkhof (Amsterdam, Netherlands)	
10.35	<b>Brain atrophy in MS: technique and interpretation</b> Hugo Vrenken (Amsterdam, Netherlands)	
10.50	<b>Understanding disability: combined MTR, spectroscopy, and diffusion</b> Claudia Leite (Sao Paulo, Brazil)	
11.05	<b>Primary progressive MS: relevance of MRI</b> Jerry Wolinsky (Houston, Texas, USA)	
11.20	<b>MR spectroscopy</b> Nicola De Stefano (Sienna, Italy)	
11.35	<b>Funcional plasticity: fMRI</b> Mara Rocca (Milan, Italy)	
11.50	Questions and answers	
12.00-13.00	Lunch	Les Jardins, 7th floor

# SCIENTIFIC PROGRAM

## WEDNESDAY, SEPTEMBER 17, 2008 (CONT.)

12.30-14.00	Satellite Symposium – European Charcot Foundation		Room 517D
	Methylation and Remyelination: Epigenetic Activation of Remyelination in Adult Brain Moderators: Fabrizio Mastronardi (Toronto, Ontario, Canada) and Otto Hommes (Nijmegen, Netherlands)		
12.30	Welcome and introduction Otto Hommes and Fabrizio Mastronardi		
12.40	Modification of DNA by methylation: environment and the epigenome Moshe Szyf (Montréal, Québec, Canada)		
13.00	Epigenetic memory loss in aging oligodendrocytes: a message for multiple sclerosis Patrizia Cassacia-Bonnefil (Newark, New Jersey, USA)		
13.20	Exogenous methylation and the suppression of murine demyelinating disease: a new strategy for treatment of MS Fabrizio Mastronardi		
13.40	Discussion		
14.00-15.30	Young Researchers Session 1		Room 517D
	Co-Chairs: Jeffrey Cohen (Cleveland, Ohio, USA) and Axel Petzold (London, United Kingdom)		
14.00	1	Assessment of Theory of Mind and emotions in multiple sclerosis Audrey Henry (Reims, France)	
14.15	2	Magnetic resonance and neuropsychological features can help to predict further disease course in benign multiple sclerosis patients Emilio Portaccio (Florence, Italy)	
14.30	3	Increased cerebrospinal fluid osteopontin concentrations in attacks of multiple sclerosis Lars Bornsen (Copenhagen, Denmark)	
14.45	4	Serum 25-hydroxyvitamin D status as a determinant of multiple sclerosis outcome following an initial demyelinating event in children Heather Hanwell (Toronto, Ontario, Canada)	
15.00	5	Altered fMRI activity in hippocampal subregions during verbal learning in multiple sclerosis Kyle Kern (Los Angeles, California, USA)	
15.15	6	Specific CNS recruitment and suppressive function of HLA-G expressing regulatory T cells in the target organ of patients with multiple sclerosis Yu-Hwa Huang (Wuerzburg, Germany)	
14.30-15:30	Sponsored Satellite Symposium – sanofi-aventis		Room 517A
	Teriflunomide: Progress in the Development of an Oral Medication for Multiple Sclerosis Co-Chairs: Paul O'Connor (Toronto, Ontario, Canada) and Ludwig Kappos (Basel, Switzerland)		
14.30	Welcome and Introduction Ludwig Kappos and Paul O'Connor		
14:35	Rationale for development: mechanism of action and pre-clinical research Reinhard Hohlfeld (Munich, Germany)		
14:50	Clinical data Mark Freedman (Ottawa, Ontario, Canada)		
15:05	Teriflunomide development plan; moving forward Aaron Miller (New York, New York, USA)		
15:20	Questions and answers		
15.30-16.00	Coffee Break		Foyer outside Rooms 520 and 524

# SCIENTIFIC PROGRAM

## WEDNESDAY, SEPTEMBER 17, 2008 (CONT.)

16.00-17.15		Young Researchers Session 2	Room 517D
		Co-Chairs: Michael Racke (Columbus, Ohio, USA) and Maria Trojano (Bari, Italy)	
16.00	7	Double impact: TWIK-related acid sensitive potassium channel 1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system Sven Meuth (Wuerzburg, Germany)	
16.15	8	MCAM/CD146 an adhesion molecule of the vasculature, defines a unique T lymphocyte subgroup and is potentially involved in lymphocyte migration to the central nervous system Romain Cayrol (Montréal, Québec, Canada)	
16.30	9	Diffuse inflammatory changes in multiple sclerosis normal-appearing white matter Marco Vercellino (Turin, Italy)	
16.45	10	USPIO-enhanced magnetic resonance imaging demonstrates diffuse inflammation in multiple sclerosis normal-appearing white matter Machteld Vellinga (Amsterdam, Netherlands)	
17.00	11	Identification of a factor inhibiting nucleocytoplasmic transport and differentiation within preserved oligodendrocyte precursor cells in multiple sclerosis: a possible cause for remyelination failure Jin Nakahara (Tokyo, Japan)	
16.00-17.00		Sponsored Satellite Symposium - MS Forum	Room 520
		Issues in MS Diagnosis	
16:00		Welcome, introduction, and pretest questions Douglas Goodin (San Francisco, California, USA)	
		Case Based Presentations:	
16.05		Myelitis 1 Ernest Willoughby (Auckland, New Zealand)	
16.25		Myelitis 2 Xavier Montalban (Barcelona, Spain)	
16.45		Posttest questions Douglas Goodin	
16.50		Panel discussion/Questions and answers	
17.30 -18.30		Sponsored Satellite Symposium - Bayer HealthCare	Room 517A
		Contemporary Approaches to MS Management Chair: Mark Freedman (Ottawa, Ontario, Canada)	
		The symposium is arranged as an expert panel discussion. Neurologists from the four corners of the world will have the chance to voice their questions directly from their hospital desk to the panel of MS experts, who will then take on and discuss these challenges directly.	
		Panelists: Xavier Montalban (Barcelona, Spain) Flavia Nelson (Houston, Texas, USA) Anthony Traboulsee (Vancouver, British Columbia, Canada) Alberto Alain Gabbai (Sao Paulo, Brazil) Ching-Piao Tsai (Taipei, Taiwan)	
18.30-20.00		Congress Welcome Reception in Exhibit Hall	Room 220

# SCIENTIFIC PROGRAM

## THURSDAY, SEPTEMBER 18, 2008

08.30-10.00		Opening Session	Room 517
		<p><b>Plenary Session 1</b> Co-Chairs: Jack Antel (Montréal, Québec, Canada) and Jerry Wolinsky (Houston, Texas, USA)</p> <p><b>Welcoming Remarks</b> On behalf of ACTRIMS,ECTRIMS and LACTRIMS Jerry Wolinsky (Houston, Texas, USA)</p> <p>On behalf of MS Societies Joyce Nelson, National Multiple Sclerosis Society Yves Savoie, Multiple Sclerosis Society of Canada</p> <p>On behalf of the Local Organizing Committee François Grand'Maison (Montreal, Quebec, Canada)</p> <p>On behalf of people affected by MS Arlette Cousture, Author</p> <p><b>ACTRIMS/CMSC+ Donald Paty Memorial Lecture</b> Introduction: Pierre Duquette (Montréal, Québec, Canada)</p> <p>12* The changing frame of MS over the centuries T. Jock Murray (Halifax, Nova Scotia, Canada)</p> <p>+ <i>The Consortium of Multiple Sclerosis Centers</i></p>	
10.00-10.30		Coffee Break	Room 220D
10.30-12.00		Parallel Session 1	Room 517A
		<p><b>Neurodegeneration and Inflammation: Which Comes First?</b> Co-Chairs: Cedric Raine (Bronx, New York, USA) and Frauke Zipp (Berlin, Germany)</p>	
10.30	13*	<p><b>Evidence for primary neurodegeneration in MS</b> Wolfgang Brück (Göttingen, Germany)</p>	
10.50	14*	<p><b>Evidence for secondary neurodegeneration in MS</b> Wayne Moore (Vancouver, British Columbia, Canada)</p>	
11.10	15	<p><b>Homogeneity of active demyelinating lesions in patients with established multiple sclerosis</b> Esther Breij (Amsterdam, Netherlands)</p>	
11.25	16	<p><b>The progression of brain atrophy is similar in drug-free MS subtypes: a longitudinal study of a large patient population</b> Antonio Giorgio (Sienna, Italy)</p>	
11.40	17	<p><b>Treatment with glatiramer acetate protects axons in patients with clinically isolated syndromes: evidence from the PreCISe trial</b> Douglas Arnold (Montréal, Québec, Canada)</p>	
10.30-12.00		Parallel Session 2	Room 517D
		<p><b>Neuromyelitis Optica (NMO)</b> Co-Chairs: Gavin Giovannoni (London, United Kingdom) and Claudia Lucchinetti (Rochester, Minnesota, USA)</p>	
10.30	18*	<p><b>Clinical pathological spectrum of NMO</b> Hans Lassman (Vienna, Austria)</p>	
10.50	19*	<p><b>Clinical features of NMO in Latin American populations</b> Marco Lana-Peixoto (Belo Horizonte, Brazil)</p>	
11.10	20*	<p><b>Treatments for NMO</b> Dean Wingerchuk (Scottsdale, Arizona, USA)</p>	
11.30	21	<p><b>Effects of B cell depletion on T cell subsets and function in neuromyelitis optica</b> Claude Genain (San Francisco, California, USA)</p>	
11.45	22	<p><b>Evaluation of different techniques to detect anti-aquaporin 4 antibodies in neuromyelitis optica patients</b> Roberto Furlan (Milan, Italy)</p>	

\* Invited lectures

# SCIENTIFIC PROGRAM

## THURSDAY, SEPTEMBER 18, 2008 (CONT.)

12.00-14.00		Lunch and Poster Viewing	Room 220D
12.45-13.45		Sponsored Satellite Symposium – Teva & sanofi-aventis	Room 517A
		<p>Improving the Course of MS: Treat Today for a Better Tomorrow            Co-Chairs: Douglas Arnold (Montréal, Québec, Canada) and Paul O'Connor (Toronto, Ontario, Canada)</p> <p>Early treatment: PreCISe-ly what the patients need            Giancarlo Comi (Milan, Italy)</p> <p>Immunomodulation and neuroprotection: MRI perspectives            Robert Zivadinov (Buffalo, New York, USA)</p> <p>Immunomodulation and neuroprotection: long term perspective            Xavier Montalban (Barcelona, Spain)</p> <p>Questions and Conclusion</p>	
14.00-15.30		Parallel Session 3	Room 517A
		<p>Brain Plasticity and Repair            Co-Chairs: Tomas Olsson (Stockholm, Sweden) and Krzysztof Selmaj (Lodz, Poland)</p>	
14.00	23*	<p>Myelin repair in the central nervous system: role of guidance molecules            Catherine Lubetzki (Paris, France)</p>	
14.20	24*	<p>Axo-glial interactions: role of transporters and glutamate receptors            Peter Stys (Ottawa, Ontario, Canada)</p>	
14.40	25*	<p>New observations on the mechanism of myelin wrapping            David Colman (Montréal, Québec, Canada)</p>	
15.00	26	<p>Roles of Sirt1 for redox-dependent fate of neural progenitors in the course of chronic autoimmune neuroinflammation            Orhan Aktas (Berlin, Germany)</p>	
15.15	27	<p>Mesenchymal stem cells as treatment for multiple sclerosis: immunomodulation versus tissue repair            Antonio Uccelli (Genoa, Italy)</p>	
14.00-15.30		Parallel Session 4	Room 517D
		<p>Antibodies: From Pathogenesis to Treatment            Co-Chairs: Bernard Hemmer (Munich, Germany) and Robert Naismith (St. Louis, Missouri, USA)</p>	
14.00	28*	<p>What is the evidence in humans that auto-antibodies to CNS antigens are pathogenic?            Jeffrey Bennett (Denver, Colorado, USA)</p>	
14.20	29*	<p>Monoclonal antibodies: the future            Steve Hauser (San Francisco, California, USA)</p>	
14.40	30	<p>Lipids as autoantigens and therapeutic immune modulators in multiple sclerosis            Peggy Ho (Stanford, California, USA)</p>	
14.55	31	<p>Alterations in cerebrospinal fluid chemokine pattern following B-cell depletion with rituximab in relapsing multiple sclerosis patients.            Anne Cross (St. Louis, Missouri, USA)</p>	
15.10	32	<p>Molecular characterization of CSF B-cell response in multiple sclerosis            Jerry Lin (New York, New York, USA)</p>	
15.30-17.00		Poster Session 1 and Coffee Break	Room 220D
		Posters P1 – P450, with authors present	

# SCIENTIFIC PROGRAM

## THURSDAY, SEPTEMBER 18, 2008 (CONT.)

17:00-17:45		Hot Topic 1	Room 517A
		Costs and Availability of MS Treatments Co-Chairs: Marco Medina (Tegucigalpa, Honduras) and Carlos Oehninger (Montevideo, Uruguay)	
17:00	33*	The impact of generics and biosimilars in interferons Victor Rivera (Mexico City, Mexico)	
17:15	34*	Costs and availability of multiple sclerosis treatments: impact on social security and public health systems in Latin America Arnoldo Soto (Caracas, Venezuela)	
17:30	35	Autologous stem cell transplantation in multiple sclerosis Amilton Barreira (Sao Paulo, Brazil)	
17:00-17:45		Hot Topic 2	Room 517D
		Genomics and Proteomics in Understanding MS Co-Chairs: Reinhard Hohlfeld (Munich, Germany) and John Richert (New York, New York, USA)	
17:00	36*	Do different disease courses display specific genomic features? Jonathan Haines (Memphis, Tennessee, USA)	
17:15	37*	Proteomics and transcriptional profiling in understanding the pathogenesis of multiple sclerosis Lawrence Steinman (Stanford, California, USA)	
17:30	38	Altered microRNA expression in lymphocytes of relapsing-remitting multiple sclerosis patients Raija Lindberg (Basel, Switzerland)	
17:00-17:45		Hot Topic 3	Room 520
		Pediatric MS Co-Chairs: Eva Havrdova (Prague, Czech Republic) and Lauren Krupp (Stony Brook, New York, USA)	
17:00	39*	Clinical features of pediatric multiple sclerosis Sylvia Tenenbaum (Buenos Aires, Argentina)	
17:15	40*	Environmental influences and immunological features of multiple sclerosis in children Brenda Banwell (Toronto, Ontario, Canada)	
17:30	41	Encephalopathic presentation of central nervous system aquaporin-4 autoimmunity in childhood Nancy Kuntz (Rochester, Minnesota, USA)	
18:00-19:00		Sponsored Satellite Symposium – EMD Serono	Room 517A
		Improving MS Treatment: Building on the Past to Prepare for the Future Co-Chairs: Gavin Giovannoni (London, United Kingdom) and Anthony Traboulsee (Vancouver, British Columbia, Canada)	
18:00		Welcome	
18:05		A decade of experience with interferons in MS Mark Freedman (Toronto, Ontario, Canada)	
18:20		Interferons and cognition in MS Stephen Rao (Cleveland, Ohio, USA)	
18:35		Interferons in MS: a look to the future Bernd Kieseier (Düsseldorf, Germany)	
18:50		Questions and panel discussion	

\* Invited lectures



# SCIENTIFIC PROGRAM

## FRIDAY, SEPTEMBER 19, 2008 (CONT.)

10.30-12.00		Parallel Session 5	Room 517A
		Advances in Imaging Techniques Co-Chairs: Douglas Arnold (Montréal, Québec, Canada) and Massimo Filippi (Milan, Italy)	
10.30	43*	OCT: window on multiple sclerosis Laura Balcer (Philadelphia, Pennsylvania, USA)	
10.50	44*	New insights into multiple sclerosis pathogenesis based on post-mortem magnetic resonance imaging studies Frederik Barkhof (Amsterdam, Netherlands)	
11.10	45	Whole brain magnetization transfer histogram metrics predict clinical disability in multiple sclerosis patients: a 5-year follow-up study Nancy Richert (Bethesda, Maryland, USA)	
11.25	46	Evaluation of multiple sclerosis lesions using gradient echo plural contrast imaging Pascal Sati (St. Louis, Missouri, USA)	
11.40	47	Relation between leakage of the blood-brain barrier as assessed by Gadofluorine M-enhanced magnetic resonance imaging and infiltration of macrophages in experimental autoimmune encephalomyelitis Guido Stoll (Wuertzburg, Germany)	
10.30-12.00		Parallel Session 6	Room 517D
		Predicting Outcomes in MS Co-Chairs: Michel Clanet (Toulouse, France) and Aaron Miller (New York, New York, USA)	
10.30	48*	Clinical and demographic predictors of early multiple sclerosis course Emmanuelle Waubant (San Francisco, California, USA)	
10.50	49*	Genes and outcomes in multiple sclerosis: predicting disease severity George Ebers (Oxford, United Kingdom)	
11.10	50*	Imaging metrics that predict outcomes Maria Pia Sormani (Genoa, Italy)	
11.30	51	Baseline magnetic resonance imaging predictors for conversion to clinically definite multiple sclerosis and McDonald multiple sclerosis, based on integrated 3-year data from the BENEFIT study Bastiaan Moraal (Amsterdam, Netherlands)	
11.45	52	The Multiple Sclerosis Severity Score (MSSS) re-examined: Expanded Disability Status Scale rank stability in the MSBase dataset increases 5 years after onset of multiple sclerosis Helmut Butzkueven (Melbourne, Australia)	
12.00-13.00		ACTRIMS Steering Committee Meeting	Room 514A
12.00-14.00		Lunch and Poster Viewing	Room 220D
12.45 - 13.45		Sponsored Satellite Symposium – Bayer HealthCare and Genzyme	Room 517A
		Researching the Potential for a New Treatment Paradigm: Alemtuzumab in MS Chair: Paul O'Connor (Toronto, Ontario, Canada)	
12.45		Welcome Paul O'Connor	
12.50		Mechanism of action Joanne Jones (Cambridge, United Kingdom)	
13.10		Current clinical evidence Krzysztof Selmaj (Lodz, Poland)	
13.25		Phase III trial programme Edward Fox (Round Rock, Texas, USA)	
13.40		Discussion	

\* Invited lectures

# SCIENTIFIC PROGRAM

## FRIDAY, SEPTEMBER 19, 2008 (CONT.)

14.00-15.40		Parallel Session 7	Room 517A
		<b>Emerging Therapies</b> Co-Chairs: Giancarlo Comi (Milan, Italy) and Rhonda Voskuhl (Los Angeles, California, USA)	
14.00	53*	Overview of oral and IV therapies for multiple sclerosis Ludwig Kappos (Basel, Switzerland)	
14.20	54*	Treatments that target macrophages and microglia Samia Khoury (Boston, Massachusetts, USA)	
14.40	55	Alemtuzumab significantly increases the proportion of clinically disease-free patients with relapsing-remitting multiple sclerosis compared to subcutaneous interferon beta-1a: results from a phase 2 study Krzysztof Selmaj (Lodz, Poland)	
14.55	56	TERMS (Tovaxin® for Early Relapsing MS) phase 2b placebo-controlled trial of autologous T-cell vaccination in patients with clinically isolated syndrome or relapsing remitting multiple sclerosis Edward Fox (Round Rock, Texas, USA)	
15.10	57	Safety, phase I/II study with intrathecal and intravenous injection of mesenchymal stem cells in patients with multiple sclerosis and amyotrophic lateral sclerosis Dimitrios Karussis (Jerusalem, Israel)	
15.25	84	Late Breaking News: Treatment of PML unfolding during monotherapy with natalizumab Ralf Gold (Bochum, Germany)	
14.00-15.30		Parallel Session 8	Room 517D
		<b>Clinical Trial Design Issues</b> Co-Chairs: Gilles Edan (Rennes, France), Henry McFarland (Bethesda, Maryland, USA)	
14.00	58*	Clinical trial design: the present and future Jerry Wolinsky (Houston, Texas, USA)	
14.20	59*	Head-to-head studies in multiple sclerosis: what do they tell us? Hans-Peter Hartung (Düsseldorf, Germany)	
14.40	60*	The ethics of clinical trials in developing countries Edgardo Cristiano (Buenos Aires, Argentina)	
15.00	61	Sample sizes for brain atrophy outcome measures in clinical trials for secondary progressive multiple sclerosis Frederik Barkof (Amsterdam, Netherlands)	
15.15	62	The search for responsive clinical endpoints in primary progressive multiple sclerosis Libertje VAE Bosma (Amsterdam, Netherlands)	
15.30-17.00		Poster Session 2 and Coffee Break	Room 220D
		Posters P451 – P498, with authors present	
17.00-17.45		Hot Topic 4	Room 517A
		<b>Bone Marrow Transplantation: Pros and Cons</b> Co-Chairs: Mark Freedman (Ottawa, Ontario, Canada) and Neil Scolding (Bristol, United Kingdom)	
17.00	63*	Evidence of effectiveness balances risk in bone marrow transplantation Athanasios Fassas (Thessaloniki, Greece)	
17.15	64*	Continuing brain damage post stem cell transplantation Imke Metz (Göttingen, Germany)	
17.30	65	Dose matters: different immunological effects following a reduced- or high-intensity autologous hematopoietic stem cell transplantation regimen in patients with multiple sclerosis Paolo Muraro (London, United Kingdom)	

# SCIENTIFIC PROGRAM

## FRIDAY, SEPTEMBER 19, 2008 (CONT.)

17.00-17.45		Hot Topic 5	Room 517D
		Management of Treatment Failure Co-Chairs: Kenneth Johnson (Baltimore, Maryland, USA) and Per Soelberg-Sorenson (Copenhagen, Denmark)	
17.00	66*	Defining treatment failure Jordi Río (Barcelona, Spain)	
17.15	67*	Management of treatment failure Richard Rudick (Cleveland, Ohio, USA)	
17.30	68	A post-marketing evaluation of the impact of neutralizing antibodies on the effectiveness of interferon beta in relapsing remitting multiple sclerosis Damiano Paolicelli (Bari, Italy)	
17.00-17.45		Hot Topic 6	Room 520
		Novel Cytokine, Chemokine and Adhesion Molecules Co-Chairs: Alberto Allain Gabbai (Sao Paulo, Brazil) and Abdolmohamad Rostami (Philadelphia, Pennsylvania, USA)	
17.00	69*	Novel adhesion molecules of the blood-brain barrier Alexander Prat (Montréal, Québec, Canada)	
17.15	70*	Multiple sclerosis immunologic and clinical behavior in parasitic infections Jorge Correale (Buenos Aires, Argentina)	
17.30	71	Notch1 signaling regulates remyelination in the adult central nervous system Gareth John (New York, New York, USA)	
18.00 - 19.00		Sponsored Satellite Symposium – Biogen Idec and Elan	Room 517D
		Discovering New Pathways in MS Chair: Bruce Trapp (Cleveland, Ohio, USA)	
		Understanding the pathophysiology of MS Bruce Trapp (Cleveland, Ohio, USA)	
		Defining the pathway of a new oral therapy Amit Bar-Or (Montréal, Québec, Canada)	
		Transforming discovery into care Richard Rudick (Cleveland, Ohio, USA)	
		The future promise of MS research Ralf Gold (Bochum, Germany)	
19.15 – 20.15		Sponsored Satellite Symposium – EMD Serono	Room 517A
		Oral Therapy: Increasing Treatment Options in MS Co-Chairs: Pierre Duquette (Montréal, Québec, Canada) and Maghild Sandberg-Wollheim (Lund, Sweden)	
19.15		Welcome	
19.20		Oral MS therapy Peter Rieckmann (Vancouver, British Columbia, Canada)	
19.35		The role of lymphocytes in the pathophysiology of MS Patrick Vermersch (Lille, France)	
19.50		Preferential lymphocyte depletion in MS Thomas Leist (Philadelphia, Pennsylvania, USA)	
20.05-20.15		Questions and panel discussion	
20.30		Congress Gala Dinner at Windsor Station	

# SCIENTIFIC PROGRAM

## SATURDAY, SEPTEMBER 20, 2008

08.30-10.00		Parallel Session 9	Room 517A
		Cognitive Dysfunction and Rehabilitation Co-Chairs: Christopher Bever (Baltimore, Maryland, USA) and Jürg Kesselring (Valens, Austria)	
8.30	72*	Exercise in multiple sclerosis neurorehabilitation George Kraft (Seattle, Washington, USA)	
8.50	73*	Rehabilitation of cognitive impairment Alan Thompson (London, United Kingdom)	
9.10	74*	Cognitive dysfunction in the Latin American multiple sclerosis population Miguel Angel Macias (Guadalajara, Mexico)	
9.30	75	Cognitive impairment, but not fatigue and depression, is associated with high cortical lesion load in multiple sclerosis Paolo Gallo (Padova, Italy)	
9.45	76	Longitudinal imaging of grey matter lesions in multiple sclerosis and the relation with neurocognition Stefan Roosendaal (Amsterdam, Netherlands)	
08.30-10.00		Parallel Session 10	Room 517D
		Late Breaking News Co-Chairs: Dimitrios Karussis (Jerusalem, Israel) and Aksel Siva (Istanbul, Turkey)	
8.30	78	Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, multicenter trial Kathleen Hawker (Columbus, Ohio, USA)	
8.45	79	Results from a phase III, 1-year, randomized, double-blind, parallel-group, dose-comparison study with glatiramer acetate in relapsing-remitting multiple sclerosis Giancarlo Comi (Milan, Italy)	
9.00	80	Nordic trial of methylprednisolone as add-on therapy to interferon-beta for the treatment of relapsing-remitting multiple sclerosis Per Soelberg Sorensen (Copenhagen, Denmark)	
9.15	81	VLA-4 antisense: an oligonucleotide targeting VLA-4 mRNA (ATL1102) significantly reduces new active lesions in patients with relapsing-remitting multiple sclerosis Volker Limmroth (Cologne, Germany)	
9.30	82	Retinal pathology in multiple sclerosis: systematic evaluation of a large autopsy series Ari Green (San Francisco, California, USA)	
9.45	83	Causal link between human herpesvirus-6 and central inflammatory demyelination Claude Genain (San Francisco, California, USA)	
10.00-10.30		Poster Session 3 (Late Breaking News) and Coffee Break Posters P899-P909, with authors present	Viger Foyer
10.30-12.00		Closing Session	Room 517D
		Plenary Session 3 Co-Chairs: Suhayl Dhib-Jalbut (New Brunswick, New Jersey, USA) and Paul O'Connor (Toronto, Ontario, Canada)	
10.30	77*	LACTRIMS Leonor Gold Memorial Lecture Introduction: Carlos Oehninger (Montevideo, Uruguay) Past, present and future of neurorehabilitation in multiple sclerosis Fernando Cáceres (Argentina)	
11.15		Summary presentations by award winners for best poster presentations Awards for best oral presentations by young researchers	
11.55		Announcement of LACTRIMS 2010 Santiago: Carlos Oehninger, President, LACTRIMS Announcement of ECTRIMS 2009 Düsseldorf: Hans-Peter Hartung, President, ECTRIMS Announcement of ACTRIMS/CMSC 2009 Atlanta: Jerry Wolinsky, Steering Committee Chair, ACTRIMS	
12.00		End of Congress	
12.00-14.00		LACTRIMS General Assembly Meeting (Executive Committee, Delegates and Members)	Room 516A